Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Herbrecht, R
Borchmann, P
Wilhelm, M
Morschhauser, F
Hess, G
Kutz, K
Comis, S
Laffranchi, BL
Engert, A
机构：
[1] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[3] Klinikum Nurnberg N, Med Klin, Nurnberg, Germany
[4] Hop Huriez, Serv Pr Bauters, Lille, France
[5] Univ Mainz, Med Klin & Poliklin 3, D-6500 Mainz, Germany
[6] Accelpharm, Basel, Switzerland
[7] Cell Therapeut Inc, Clin Dept, Milan, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2489
引用
收藏
页码：682A / 683A
页数：2
相关论文
共 50 条
  • [1] A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, P
    Schnell, R
    Morschhauser, F
    Hess, G
    Harousseau, JL
    Herbrecht, R
    Derigs, HG
    Dreyfus, F
    Schouten, HC
    Engert, A
    Camboni, G
    BLOOD, 2003, 102 (11) : 642A - 642A
  • [2] Results of. a phase II study of pixantrone in combination with cyclophospamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Kutz, Klaus
    Stromatt, Scott
    Engert, Andreas
    BLOOD, 2006, 108 (11) : 160A - 160A
  • [3] Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Cernohous, Paul
    Veals, Susan A.
    Singer, Jack W.
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 620 - 628
  • [4] A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma
    Lim, Soon-Thye
    Fayad, L.
    Tulpule, A.
    Modiano, M.
    Cabanillas, F.
    Laffranchi, B.
    Allievi, C.
    Bernareggi, A.
    Levine, Alexandra M.
    LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 374 - 380
  • [5] Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma (NHL)
    Levine, A
    Fayad, L
    Modiano, M
    Camboni, G
    Cabinallas, F
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 110 - 110
  • [6] Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.
    Wiemik, Peter H.
    Lossos, Izidore
    Tuscano, Joseph
    Justice, Glen
    Vose, Julie M.
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2006, 108 (11) : 160A - 161A
  • [7] Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
    Borchmann, P
    Morschhauser, F
    Parry, A
    Schnell, R
    Harousseau, JL
    Gisselbrecht, C
    Rudolph, C
    Wilhelm, M
    Derigs, HG
    Pfreundschuh, M
    Camboni, G
    Engert, A
    HAEMATOLOGICA, 2003, 88 (08) : 888 - 894
  • [8] Phase II study of cyclophosphamide, prednisone, and etoposide (CEOP-E) lymphoma epirubicin, vincristine, for aggressive non-Hodgkin's
    Kim, JG
    Sohn, SK
    Kim, DH
    Baek, JH
    Park, TI
    Lee, KB
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (06) : 820 - 825
  • [9] Phase-II study of BBR 2778, a new aza-anthracenedione, in patients with relapsed aggressive non-Hodgkin lymphomas.
    Borchmann, P
    Morschhauser, F
    Schnell, R
    Harousseau, JL
    Gisselbrecht, C
    Rudolph, C
    Wilhelm, M
    Derigs, H
    Kutz, K
    Leynardier, D
    Verdi, E
    Camboni, G
    Engert, A
    BLOOD, 2001, 98 (11) : 341A - 341A
  • [10] Preliminary results of a phase II trial of pegylated liposomal doxorubicin (Doxil), rituxan, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Khan, AU
    Mohrbacher, A
    Weitz, IC
    Espina, BM
    Boswell, WD
    Nathwani, BN
    Levine, AM
    BLOOD, 2003, 102 (11) : 286B - 286B
12345